SCHEMBL24629477

SCHEMBL24629477

Nc1ccc(C2CCN(C(=O)OCC3c4ccccc4-c4ccccc43)CC2)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP7 O15540 2/20 0.43
FABP5 Q01469 2/20 0.43
EPHX2 P34913 1/20 0.39
KMT2A Q03164 3/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
GRM5 P41594 2/20 0.38
ALDH1A1 P00352 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
HSD17B10 Q99714 1/20 0.38
F10 P00742 2/20 0.37
USP2 O75604 1/20 0.37
CHRM2 P08172 1/20 0.37
CHRM5 P08912 1/20 0.37
CHRM3 P20309 1/20 0.37
MEN1 O00255 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29769215 1.00 FABP7 (0.43) FABP7FABP5EPHX2KMT2AMAPT
SCHEMBL6712704 0.83 FABP5 (0.44) FABP7FABP5EPHX2KMT2AMAPT
SCHEMBL34472759 0.83 FABP7 (0.43) FABP7FABP5KMT2AALDH1A1KDM4E
SCHEMBL29769077 0.80 EPHX2 (0.42) EPHX2KMT2AMAPTHTTNPSR1
SCHEMBL874549 0.78 SMN1; SMN2 (0.48) FABP7FABP5EPHX2KMT2AMAPT
SCHEMBL29409631 0.78 KMT2A (0.42) FABP7FABP5EPHX2KMT2ANPSR1
SCHEMBL22589466 0.78 KMT2A (0.42) FABP7FABP5EPHX2KMT2ANPSR1
SCHEMBL27841040 0.78 KMT2A (0.48) FABP7FABP5EPHX2KMT2AMAPT
SCHEMBL22397770 0.77 POLB (0.52) FABP7FABP5EPHX2KMT2AMAPT
SCHEMBL13327274 0.77 POLB (0.52) FABP7FABP5EPHX2KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240132480-A1 INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC. 2024-04-25 US disclosed
WO-2022150574-A1 INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE CORNELL UNIVERSITY (US) 2022-07-14 WO disclosed
WO-2022150574-A1 INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE CORNELL UNIVERSITY (US) 2022-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132480-A1 INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE DLD, GCDH, DLAT FABP7 968/4885FABP5 660/4885EPHX2 1717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.